Cargando…
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform co...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046237/ https://www.ncbi.nlm.nih.gov/pubmed/33852571 http://dx.doi.org/10.1371/journal.pone.0249123 |
_version_ | 1783678810220134400 |
---|---|
author | Khairnar, Rahul Pugh, Stephanie L. Sandler, Howard M. Lee, W. Robert Villalonga Olives, Ester Mullins, C. Daniel Palumbo, Francis B. Bruner, Deborah W. Shaya, Fadia T. Bentzen, Soren M. Shah, Amit B. Malone, Shawn C. Michalski, Jeff M. Dayes, Ian S. Seaward, Samantha A. Albert, Michele Currey, Adam D. Pisansky, Thomas M. Chen, Yuhchyau Horwitz, Eric M. DeNittis, Albert S. Feng, Felix Y. Mishra, Mark V. |
author_facet | Khairnar, Rahul Pugh, Stephanie L. Sandler, Howard M. Lee, W. Robert Villalonga Olives, Ester Mullins, C. Daniel Palumbo, Francis B. Bruner, Deborah W. Shaya, Fadia T. Bentzen, Soren M. Shah, Amit B. Malone, Shawn C. Michalski, Jeff M. Dayes, Ian S. Seaward, Samantha A. Albert, Michele Currey, Adam D. Pisansky, Thomas M. Chen, Yuhchyau Horwitz, Eric M. DeNittis, Albert S. Feng, Felix Y. Mishra, Mark V. |
author_sort | Khairnar, Rahul |
collection | PubMed |
description | PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Eligible patients included men >18 years with a known diagnosis of low-risk PC. Patient HRQoL data were collected using EPIC and health utilities were obtained using EQ5D. Data were divided into an estimation sample (n = 765, 70%) and a validation sample (n = 327, 30%). The mapping algorithms that capture the relationship between the instruments were estimated using ordinary least squares (OLS), Tobit, and two-part models. Five-fold cross-validation (in-sample) was used to compare the predictive performance of the estimated models. Final models were selected based on root mean square error (RMSE). RESULTS: A total of 565 patients in the estimation sample had complete information on both EPIC and EQ5D questionnaires at baseline. Mean observed EQ5D utility was 0.90±0.13 (range: 0.28–1) with 55% of patients in full health. OLS models outperformed their counterpart Tobit and two-part models for all pre-determined model specifications. The best model fit was: “EQ5D utility = 0.248541 + 0.000748*(Urinary Function) + 0.001134*(Urinary Bother) + 0.000968*(Hormonal Function) + 0.004404*(Hormonal Bother)– 0.376487*(Zubrod) + 0.003562*(Urinary Function*Zubrod)”; RMSE was 0.10462. CONCLUSIONS: This is the first study to identify a comprehensive set of mapping algorithms to generate EQ5D utilities from EPIC domain/ sub-domain scores. The study results will help estimate quality-adjusted life-years in PC economic evaluations. |
format | Online Article Text |
id | pubmed-8046237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-80462372021-04-21 Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 Khairnar, Rahul Pugh, Stephanie L. Sandler, Howard M. Lee, W. Robert Villalonga Olives, Ester Mullins, C. Daniel Palumbo, Francis B. Bruner, Deborah W. Shaya, Fadia T. Bentzen, Soren M. Shah, Amit B. Malone, Shawn C. Michalski, Jeff M. Dayes, Ian S. Seaward, Samantha A. Albert, Michele Currey, Adam D. Pisansky, Thomas M. Chen, Yuhchyau Horwitz, Eric M. DeNittis, Albert S. Feng, Felix Y. Mishra, Mark V. PLoS One Research Article PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Eligible patients included men >18 years with a known diagnosis of low-risk PC. Patient HRQoL data were collected using EPIC and health utilities were obtained using EQ5D. Data were divided into an estimation sample (n = 765, 70%) and a validation sample (n = 327, 30%). The mapping algorithms that capture the relationship between the instruments were estimated using ordinary least squares (OLS), Tobit, and two-part models. Five-fold cross-validation (in-sample) was used to compare the predictive performance of the estimated models. Final models were selected based on root mean square error (RMSE). RESULTS: A total of 565 patients in the estimation sample had complete information on both EPIC and EQ5D questionnaires at baseline. Mean observed EQ5D utility was 0.90±0.13 (range: 0.28–1) with 55% of patients in full health. OLS models outperformed their counterpart Tobit and two-part models for all pre-determined model specifications. The best model fit was: “EQ5D utility = 0.248541 + 0.000748*(Urinary Function) + 0.001134*(Urinary Bother) + 0.000968*(Hormonal Function) + 0.004404*(Hormonal Bother)– 0.376487*(Zubrod) + 0.003562*(Urinary Function*Zubrod)”; RMSE was 0.10462. CONCLUSIONS: This is the first study to identify a comprehensive set of mapping algorithms to generate EQ5D utilities from EPIC domain/ sub-domain scores. The study results will help estimate quality-adjusted life-years in PC economic evaluations. Public Library of Science 2021-04-14 /pmc/articles/PMC8046237/ /pubmed/33852571 http://dx.doi.org/10.1371/journal.pone.0249123 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Khairnar, Rahul Pugh, Stephanie L. Sandler, Howard M. Lee, W. Robert Villalonga Olives, Ester Mullins, C. Daniel Palumbo, Francis B. Bruner, Deborah W. Shaya, Fadia T. Bentzen, Soren M. Shah, Amit B. Malone, Shawn C. Michalski, Jeff M. Dayes, Ian S. Seaward, Samantha A. Albert, Michele Currey, Adam D. Pisansky, Thomas M. Chen, Yuhchyau Horwitz, Eric M. DeNittis, Albert S. Feng, Felix Y. Mishra, Mark V. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title_full | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title_fullStr | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title_full_unstemmed | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title_short | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 |
title_sort | mapping expanded prostate cancer index composite to eq5d utilities to inform economic evaluations in prostate cancer: secondary analysis of nrg/rtog 0415 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046237/ https://www.ncbi.nlm.nih.gov/pubmed/33852571 http://dx.doi.org/10.1371/journal.pone.0249123 |
work_keys_str_mv | AT khairnarrahul mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT pughstephaniel mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT sandlerhowardm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT leewrobert mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT villalongaolivesester mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT mullinscdaniel mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT palumbofrancisb mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT brunerdeborahw mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT shayafadiat mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT bentzensorenm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT shahamitb mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT maloneshawnc mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT michalskijeffm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT dayesians mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT seawardsamanthaa mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT albertmichele mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT curreyadamd mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT pisanskythomasm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT chenyuhchyau mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT horwitzericm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT denittisalberts mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT fengfelixy mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 AT mishramarkv mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415 |